Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2008-03-11
2008-03-11
Yu, Misook (Department: 1642)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
Reexamination Certificate
active
11138242
ABSTRACT:
Isolated polynucleotides encoding Cynomolgus monkey prostate specific antigen and polypeptides obtainable from the polynucleotides and uses are disclosed.
REFERENCES:
patent: 5266489 (1993-11-01), Rey-Senelonge et al.
patent: 5558860 (1996-09-01), Ross et al.
patent: 5585254 (1996-12-01), Maxwell et al.
patent: 5616326 (1997-04-01), Spibey
patent: 5693530 (1997-12-01), Schat et al.
patent: 5744143 (1998-04-01), Ross et al.
patent: 5756103 (1998-05-01), Paoletti et al.
patent: 5766599 (1998-06-01), Paoletti et al.
patent: 5795872 (1998-08-01), Ricigliano et al.
patent: 5858368 (1999-01-01), Smith et al.
patent: 5958425 (1999-09-01), Ross et al.
patent: 5990091 (1999-11-01), Tartaglia et al.
patent: 6020172 (2000-02-01), Both
patent: 6086890 (2000-07-01), Mittal et al.
patent: 6086891 (2000-07-01), Hurwitz et al.
patent: 6099847 (2000-08-01), Tobin et al.
patent: 6140114 (2000-10-01), Klatzmann et al.
patent: 6221136 (2001-04-01), Liu et al.
patent: 6274147 (2001-08-01), Vakharia et al.
patent: 2002/0099189 (2002-07-01), Savizky et al.
patent: 2003/0064397 (2003-04-01), Spancake et al.
patent: WO 87/06262 (1987-10-01), None
patent: WO 93/19183 (1993-09-01), None
patent: WO 95/20660 (1995-08-01), None
patent: WO 97/35021 (1997-09-01), None
Lundwall, et al., “Molecular cloning of human prostate specific antigen cDNA,” FEBS Letters, 214(2): 317-322 (1987).
Xiang, et al., “A Replication-Defective Human Adenovirus Recombinant Serves as a Highly Efficacious Vaccine Carrier,” Virology, 219: 220-227 (1996).
Fries, et al., “Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system,” Vaccine, 14(5): 428-434 (1996).
Gōnoz{hacek over (o)}l, et al., “Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate,” Vaccine 13(12): 1080-1085 (1995).
Xue, et al., “Induction of Human Cytotoxic T Lymphocytes Specific for Prostate-Specific Antigen,” The Prostate, 30: 73-78 (1997).
Lubeck, et al., “Immunogenicity and Efficacy Testing in Chimpanzees of an Oral Hepatitis B Vaccine Based on Live Recombinant Adenovirus,” Proceedings of the National Academy of Science USA, 86: 6763-6767 (1989).
Cooney, et al., “Enhanced Immunity to Human Immunodeficiency Virus (HIV) Envelope Elicited by a Combined Vaccine Regimen Consisting of Priming with a Vaccinia Recombinant Expressing HIV Envelope and Boosting with gp160 protein,” Proceedings of the National Academy of Science USA, 90: 1882-1886 (1993).
Wei, et al., “Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: Implications for tolerance and immunotherapy,” Proceedings of the National Academy of Science USA, 94: 6369-6374 (1997).
Sioud, et al., “Generation of an effective anti-tumor immunity after immunization with xenogeneic antigens,” European Journal of Immunology, 33: 38-45 (2003).
Wolchok, et al, “DNA Vaccines: An Active Immunization Strategy for Prostate Cancer,” Seminars in Oncology, 30(5): 659-666 (2003).
Watt, et al, “Human Prostate-Specific Antigen: Structural and Functional Similarity with Serine Proteases,” Proceedings of the National Academy of Science, 83: 3166-3170 (1986).
Pialoux, et al., “A Prime-Boost Approach to HIV Preventive Vaccine Using a Recombinant Canarypox Virus Expressing Glycoprotein 160 (MN) followed by a Recombinant Glycoprotein 160 (MN/LAI),” Aids Research and Human Retroviruses, 11(3): 373-381 (1995).
David, et al., “Unusual Alternative Splicing within the Human Kallikrein GenesKLK2andKLK3Gives Rise to Novel Prostate-specific Proteins,” The Journal of Biological Chemistry, 277(20): 18084-18090 (2002).
Andersson, et al., “Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 2 Recombinant Canarypox (ALVAC) Vaccine Candidate in Cynomolgus Monkeys,” The Journal of Infectious Diseases, 174: 977-985 (1996).
Judith A. Clements, “The Glandular Kallikrein Family of Enzymes: Tissue-Specific Expression and Hormonal Regulation,” Endocrine Reviews, 10(4): 393-419 (1989).
Correale, et al., “In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived from Prostate-Specific Antigen,” Journal of the National Cancer Institute, 89(4): 293-300 (1997).
Gentz, et al., “Bioassay for Trans-Activation Using Purified Human Immunodeficiency Virus tat-Encoded protein: Trans-activation requires mRNA Synthesis,” Proceedings of the National Academy of Science USA, 86: 821-824 (1989).
Graham, et al., “Vaccination of Vaccinia-Naive Adults with Human Immunodeficiency Virus Type I gp160 Recombinant Vaccinia Virus in a Blinded, Controlled, Randomized Clinical Trial,” Journal of Infectious Diseases, 166: 244-252 (1992).
Habenicht, et al., “Induction of Estrogen-Related Hyperplastic changes in the Prostate of the Cynomolgus Monkey (Macaca fascicularis) by Androstenedione and its Antagonization by Aromatase Inhibitor 1-Methyl-Androsta-1,4-Diene-3, 17-Dione,” The Prostate, 11: 313-326 (1987).
Liu, et al., “Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2,” Blood, 102(5): 1815-1823 (2003).
McElrath, et al., “Immune Responses Elicited by Recombinant Vaccinia-Human Immunodeficiency Virus (HIV) Envelope and HIV Envelope Protein: Analysis of the Durability of Responses and Effect of Repeated Boosting,” Journal of Infectious Diseases, 169: 41-47 (1994).
Prevec, et al., “A Recombinant Human Adenovirus Vaccine against Rabies,” Journal of Infectious Diseases, 161: 27-30 (1990).
Stamey, et al., “Prostate-Specific Antigen As a Serum Marker for Adenocarcinoma of the Prostate,” The New England Journal of Medicine, 317(15): 909-916 (1987).
Watt, et al., “Human Prostate-Specific Antigen: Structural and Functional Similarity with Serine Proteases,” Proceedings of the National Academy of Sciences USA, 83: 3166-3170 (1986).
Wilson, et al., “The Structure of an Antigenic Determinant in a Protein,” Cell, 37: 767-778 (1984).
Riegman, et al., “Molecular Cloning and Characterization of Novel Prostate Antigen cDNA's,” Biochemical and Biophysical Research Communications, 155(1): 181-188 (1988).
Kaplitt, et al., “Expression of a Functional Foreign Gene In Adult Mammalian Brain following in Vivo Transfer via a Herpes Simplex Virus Type I Defective Viral Vector,” Molecular and Cellular Neurosciences, 2: 320-330 (1991).
Wolchok, et al., “Alternative roles for interferon-gamma in the immune response to DNA vaccines encoding related melanosomal antigens,” Cancer Immunity, 1: 9-18 (2001).
Gilardi-Hebenstreit, et al., “Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use a live vaccine,” Journal of General Virology, 71: 2425-2431 (1990).
Kamischke, et al., “The Cynomolgus Monkey Prostate Under Physiological and Hypogonadal Conditions: an Ultrasonographic Study,” The Journal of Urology, 157: 2340-2344 (1997).
Kim, et al., “Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine,” Oncogene, 17: 3125-3135 (1998).
Kim, et al., “Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen,” Oncogene, 20: 4497-4506 (2001).
Centrotide® Package Insert, Manufactured for: Serono, Inc., Rockland, Massachusetts.
“Aeterna prostate treatment accepted by FDA,” Pharmaceutical Business Review, www. pharmaceutical-business-review.com/article, Jan. 16, 2007.
Jungwirth, et al., “Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrolex and Bombesin anta
Marshall Deborah J.
Snyder Linda A.
Aeder Sean E
Baumeister Kirk
Centocor, Inc.
Yu Misook
LandOfFree
Cynomolgus prostate specific antigen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cynomolgus prostate specific antigen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cynomolgus prostate specific antigen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3915279